Peer Review History

Original SubmissionOctober 14, 2022
Decision Letter - Gulzhanat Aimagambetova, Editor

PONE-D-22-28450Human papillomavirus genotype distribution among women with and without cervical cancer: Implication for vaccination and screening in Ghana.PLOS ONE

Dear Dr. Yvonne Nartey,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by December 29, 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Gulzhanat Aimagambetova

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1.  Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf  and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

3. Our staff editors have determined that your manuscript is likely within the scope of our Early Detection, Screening and Diagnosis of Cancer Call for Papers. This editorial initiative is headed by in-house PLOS editors. This Call for Papers aims to explore recent advances in the early detection of cancer and implications of these advances for patient survival. Additional information can be found on our announcement page: https://collections.plos.org/call-for-papers/early-detection-screening-and-diagnosis-of-cancer/

If you would like your manuscript to be considered for this collection, please let us know in your cover letter and we will ensure that your paper is treated as if you were responding to this call. Please note that being considered for the Call for Papers does not require additional peer review beyond the journal’s standard process and will not delay the publication of your manuscript if it is accepted by PLOS ONE. If you would prefer to remove your manuscript from collection consideration, please specify this in the cover letter.

4. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met.  Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

5. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an well written article on the topic of HPV in Ghana. The analysis presented in the paper are really interesting. I would leave a minor comment on enriching the discussion. In the last paragraph, you might include two or three sentences on Ghana's existing HPV screening program and how your study findings can improve the existing approach.

Reviewer #2: Nartey and colleagues present an interesting study on the prevalence of different HPV genotypes among women in Ghana. Studies like this are particularly important in understanding if newer vaccines are needed to treat different strains and the effectiveness of HPV vaccination in other areas. Additional comments are noted below.

*In line 109, authors state that HPV vaccine effectiveness studies have mainly been conducted among Caucasians. While there is a lack of diversity in research participants in biomedical research, this statement ignores the positive gains made in preventing cervical cancer in multiple countries that has had benefits for people across multiple races. Additionally, this statement seems out of place considering the authors do not mention race and ethnicity throughout the article. The authors should consider either removing this statement are include additional information about how research is needed among different races/ ethnicities and results from this study differ from previous studies conducted among majority Caucasian populations.

*It's unclear if the authors are trying to promote the usage of currently available HPV vaccines in Ghana or if they are requesting a new one. It would be helpful if the authors were clearer about this. Especially in lines 470-471 in the conclusion.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Abdullah Nurus Salam Khan

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

22nd November, 2022

Dear Dr Aimagambetova,

We thank you for taking the time to carefully read our manuscript and for the valuable comments you have provided, which helped us in improving the revised paper that we are re-submitting. We have made all requested changes, ensured it complies with all the journal requirements.

Yours truly,

Dr Yvonne Nartey

Here is our point-by-point response to the reviewer’s comments:

(Reviewer comments in bold)

This is an well written article on the topic of HPV in Ghana. The analysis presented in the paper are really interesting. I would leave a minor comment on enriching the discussion. In the last paragraph, you might include two or three sentences on Ghana's existing HPV screening program and how your study findings can improve the existing approach.

Response: We have, accordingly, added the following sentence to the last paragraph of the discussion session.

“Currently, Ghana do not have a national HPV screening program for cervical cancer. However, there are some public and private health facilities that offer such services. The current study provides useful information on the type of HPV likely to lead to cervical cancer and may help in the triage of women for follow-ups. “ - Page 20, paragraph 1, line 2.

Nartey and colleagues present an interesting study on the prevalence of different HPV genotypes among women in Ghana. Studies like this are particularly important in understanding if newer vaccines are needed to treat different strains and the effectiveness of HPV vaccination in other areas. Additional comments are noted below.

In line 109, authors state that HPV vaccine effectiveness studies have mainly been conducted among Caucasians. While there is a lack of diversity in research participants in biomedical research, this statement ignores the positive gains made in preventing cervical cancer in multiple countries that has had benefits for people across multiple races. Additionally, this statement seems out of place considering the authors do not mention race and ethnicity throughout the article. The authors should consider either removing this statement are include additional information about how research is needed among different races/ ethnicities and results from this study differ from previous studies conducted among majority Caucasian populations.

Response: We have, accordingly, revised the sentence to reflect the reviewer comment. The sentence has been altered to the following:

“The available HPV vaccines have activity against up to nine HPV types (6, 11, 16,18, 31 33 45 52 58)”. – Page5, paragraph 2, line 7.

It's unclear if the authors are trying to promote the usage of currently available HPV vaccines in Ghana or if they are requesting a new one. It would be helpful if the authors were clearer about this. Especially in lines 470-471 in the conclusion.

Response: We have, accordingly, revised the sentence to reflect the reviewer comment. The sentence has been altered to the following:

“HPV DNA testing for cervical screening and multivalent vaccine targeted at the most prevalent HPV types will be a valuable contribution to Ghana’s cervical cancer control programme than the currently available licensed vaccine.” – page 20, paragraph 2, line 8.

Attachments
Attachment
Submitted filename: Response to reviewer.docx
Decision Letter - Gulzhanat Aimagambetova, Editor

Human papillomavirus genotype distribution among women with and without cervical cancer: Implication for vaccination and screening in Ghana.

PONE-D-22-28450R1

Dear Dr. Yvonne Nartey,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Gulzhanat Aimagambetova

Academic Editor

PLOS ONE

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a very important paper on the topic. Authors have addressed the comments and feedback adequately.

Reviewer #2: The authors did a great job in addressing reviewer comments! I have no additional comments or concerns about this publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Abdullah Nurus Salam Khan

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Gulzhanat Aimagambetova, Editor

PONE-D-22-28450R1

Human papillomavirus genotype distribution among women with and without cervical cancer: Implication for vaccination and screening in Ghana.

Dear Dr. Nartey:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Gulzhanat Aimagambetova

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .